Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

NCT02115243 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Melanoma

Interventions

DRUG: Ipilimumab

Sponsor

Duke University